Skip to content
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Corporate Presentation
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Press Releases
Contact Us
Menu
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Corporate Presentation
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Press Releases
Contact Us
Post Tag: Publications
August 20, 2024
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
Read More »
August 20, 2024
Entera Bio to Participate in Upcoming Investor and Scientific Conferences – HCW, ASBMR, and Evercore
Read More »
March 14, 2024
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Read More »
November 14, 2023
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
Read More »
September 12, 2023
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
Read More »
June 7, 2023
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
Read More »
May 3, 2023
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
Read More »
April 26, 2023
Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board
Read More »
April 3, 2023
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
Read More »
March 31, 2023
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
Read More »
March 23, 2023
Entera Bio Regains Compliance with Nasdaq Listing Requirements
Read More »
February 16, 2023
SVB Securities Global Biopharma Conference
Read More »
Load More
Thank You
Message Sent!
We will get back to you soon